Cryo-Cell International Reports Q2 2025 Financials: Revenue Slightly Down by 1%, Net Income Drops to $356,000, EPS Falls to $0.04

Reuters
07/16
Cryo-Cell International Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Financials: Revenue Slightly Down by 1%, Net Income Drops to $356,000, EPS Falls to $0.04

Cryo-Cell International Inc. (NYSE American LLC: CCEL), the pioneering private cord blood bank, has released its financial results for the fiscal second quarter ending May 31, 2025. The company reported revenues of $7.9 million, marking a slight decrease from $8.0 million in the same period of fiscal 2024. The revenue breakdown for the second quarter of 2025 included $7.87 million from processing and storage fees, $43,000 from public banking, and $14,000 from product sales, compared to $7.97 million, $41,000, and $36,000, respectively, in the previous year. Net income for the quarter stood at $356,000, or $0.04 per basic and diluted share, a decline from $656,000, or $0.08 per share, in the equivalent quarter of the prior year. The company did not provide any outlook or guidance in the current release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryo-Cell International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250715194484) on July 15, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10